Stock Price

As online reviews face a crisis of trust, a Bay Area company doubles down on a physical directory, betting that verified quality is worth its weight in paper.

A legal battle erupts in Nevada as Getchell Gold Corp. defends its Fondaway Canyon project against a rival's claim on its most valuable ground.

The bank's Q1 2026 earnings show improved interest margins and steady dividends, painting a picture of resilience in a complex Hawaiian economy.

Facing Nasdaq delisting, Chinese IT firm Hitek Global enacts a massive reverse stock split. Is this a strategic reset or a desperate last stand for survival?

Sieve Capital launches a public campaign against Americold Chairman Mark Patterson, citing a -50% return and a history of poor corporate governance.

The massive C$5.15 billion deal transforming Plains into a crude oil pure-play and Keyera into an NGL giant faces a delay amid a Competition Bureau review.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

NIP Group faces a delisting threat after its stock plunged. With 180 days to recover, can its unique esports and Bitcoin model win back investors?

Allspring's closed-end funds offer tempting yields, but tiny shifts in their monthly payouts reveal a complex story of risk, return, and capital erosion.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

Cocoa prices are falling, but your chocolate bar costs more. Discover why consumers are embracing this shift by reaching for premium, pricier treats.

Rithm Capital declared its 52nd straight dividend. Is its high yield and analyst praise enough to overcome recent stock woes and market skepticism?

The non-prime lender struck a deal with lenders to ensure liquidity, but it comes at a high price amid massive loan losses and scrutiny of its LendCare unit.

With the appointment of Jack Azagury as CEO, Insight Enterprises signals an aggressive pivot to AI, banking on his transformation expertise to lead a new era.

Health-Ade's new campaign with Lindsay Lohan is more than celebrity sparkle; it's a calculated play for the booming wellness market. Here's the inside story.

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

For the 12th straight year, TE Connectivity is one of Ethisphere's Most Ethical Companies. What does this sustained commitment to integrity mean for the tech industry?

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

The supply chain software firm nearly doubles its share repurchase plan, signaling deep confidence amid a strategic push for AI innovation and global growth.

Aerospace tech firm Merlin lands on NASDAQ, securing capital to scale its AI-powered autonomous flight system for military and future civilian aircraft.